ScholarIQanswers from OpenAlex
Izumi City General Hospital
InstitutionResearch output, impact & collaborations
Izumi City General Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Izumi City General Hospital?
ScholarIQrecord summary
Izumi City General Hospital is a research organisation in Osaka, JP. OpenAlex records 1,428 works and 43,620 citations for it. 439 researchers list it as their most recent affiliation.
How many works does Izumi City General Hospital have?
ScholarIQindexed works
Izumi City General Hospital has 1,428 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Izumi City General Hospital have?
ScholarIQcitation count
Izumi City General Hospital has 43,620 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Izumi City General Hospital?
ScholarIQresearcher count
Izumi City General Hospital has 439 researchers in the ScholarIQ index.
What is the average h-index at Izumi City General Hospital?
ScholarIQavg h-index
Izumi City General Hospital has an average h-index of 113 in OpenAlex.
What is the ROR of Izumi City General Hospital?
ScholarIQror
The ROR for Izumi City General Hospital is on the source record.
What is the OpenAlex record for Izumi City General Hospital?
ScholarIQopenalex
The OpenAlex for Izumi City General Hospital is on the source record.
Who are the most-cited researchers behind Izumi City General Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Izumi City General Hospital?
ScholarIQmost cited works
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
Hisashi Saji, Morihito Okada, Masahiro Tsuboi, Ryu Nakajima, Kenji Suzuki, Keiju Aokage, Tadashi Aoki, Jiro Okami, Ichiro Yoshino, Hiroyuki Ito, Norihito Okumura, Masafumi Yamaguchi, Norihiko Ikeda, Masashi Wakabayashi, Kenichi Nakamura, Haruhiko Fukuda, Shinichiro Nakamura, Tetsuya Mitsudomi, Shun‐ichi Watanabe, Hisao Asamura
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta, Yuichi Ishikawa, Hideki Kimura, Tetsuya Mitsudomi, Yoshiro Tanio, Hiroyuki Mano
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Zsolt Pápai-Székely, Hiroaki Akamatsu, Bivas Biswas, Alexander I. Spira, Jeffrey Crawford, Ha Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck
How much of the research on Izumi City General Hospital is open access?
ScholarIQopen access share
75%OPEN ACCESS